Clinical Trials Logo

Filter by:
NCT ID: NCT05617469 Recruiting - Gastric Cancer Clinical Trials

DLCS for Predicting Neoadjuvant Chemotherapy Response

Start date: July 1, 2022
Phase:
Study type: Observational

The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of this study was to develop and visualized a radio-clinical biomarker from pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC patients.

NCT ID: NCT05617430 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

Start date: November 2, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.

NCT ID: NCT05616533 Recruiting - Clinical trials for Precise Prediction of Therapy Efficiency

Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric Cancer

Start date: September 12, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to compare the tumor response in gastric cancer patients given neoadjuvant chemotherapy with the corresponding result obtained from zebrafish patient-derived tumor xenograft(PDX) model given the same regimen. The main question it aims to answer is whether this PDX model of zebrafish could accurately predict the effect of chemotherapy in advanced gastric cancer. Participants will be given the standard neoadjuvant treatment administrated by their own doctors and tumor response will be observed and recorded. Meanwhile, tumor samples derived from patients before chemotherapy will be transplanted to zebrafish and the same regimen will be given to the PDX models correspondingly. The tumor response data both from clinical practice and PDX model platform will be analysed and compared to evaluate the power of this zebrafish model platform in drug efficiency prediction.

NCT ID: NCT05616520 Recruiting - Clinical trials for Peripheral Arterial Disease

Treatment of Complex Femoropopliteal Artery Lesions Using Drug-coated PTA Balloon

Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

Although DCBs had been widely applicable after registration, there are still lack of clinical data and evidence in the real world condition of Chinese population. This data collection aims to perform regularly clinical follow up to guide the standardized diagnosis and treatment of patients post-operatively, in order to achieve the maximum clinical benefits of these patients, as well as improve the development of the field of peripheral artery disease treated by drug-coated balloon.

NCT ID: NCT05616494 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer

Start date: December 6, 2022
Phase: Phase 2
Study type: Interventional

This trial is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) in patients with pancreatic cancer.

NCT ID: NCT05616468 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Start date: December 30, 2022
Phase: Early Phase 1
Study type: Interventional

This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma

NCT ID: NCT05616416 Recruiting - Emergency Medicine Clinical Trials

International Big Data Centre in Emergency Medicine

Start date: January 1, 2011
Phase:
Study type: Observational

This observational study aims to use electronic health records to build an International Big Data Centre in Emergency Medicine, within the Institute of Sciences in Emergency Medicine (ISEM) at the Guangdong Provincial People's Hospital. The main questions it seeks to answer are not limited to the following: - Identify the relationship between Emergency Department Length of Stay (EDLOS), Mortality, and Adverse Events (AE) - Identify the risk factors associated with high mortality and AE rate among patients who experience prolonged EDLOS - Other research questions related to emergency medicine, such as building prediction and cluster models for acute diseases

NCT ID: NCT05616390 Recruiting - Clinical trials for Hepatocellular Carcinoma

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Start date: November 9, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma

NCT ID: NCT05615727 Recruiting - Insomnia Clinical Trials

Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia

Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

Insomnia is a significant public health burden, increasing work absenteeism and health care costs in a large proportion of the population. It causes altered cognition, emotional disturbances, and reduced quality of life. The purpose of this study is to determine whether the sleep promoting effect of dexmedetomidine is superior to the conventional sleep promoting drug, zolpidem. The main outcome of this study is to measure the time taken to fall asleep. Investigators will also look at incidences of wakening after sleep onset, sleep quality and wake time during sleep.

NCT ID: NCT05615545 Recruiting - Sarcoma Clinical Trials

Cryoablation for Advanced Bone and Soft Tissue Tumors

Start date: March 10, 2022
Phase:
Study type: Observational

This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. All eligible patients were enrolled. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.